Active — Not RecruitingNot Applicable

PET Imaging of Giant Cell and Takayasu Arteritis

United Kingdom27 participantsStarted 2019-06-25

Plain-language summary

While 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging is often included in the diagnostic work-up of patients with large-vessel vasculitis (LVV), 18F-FDG lacks specificity for inflammatory cells and has limited ability to track therapy response. Moreover, high background 18F-FDG uptake in the brain and myocardium largely precludes imaging temporal arteritis in giant-cell arteritis (GCA) and coronary artery involvement in Takayasu arteritis respectively. These limitations of 18F-FDG for imaging LVV highlight important unmet clinical needs, which might be overcome by using a somatostatin receptor subtype-2 (SST2) PET tracer.

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. New clinical diagnosis or acute flare of LVV (Giant-cell arteritis or Takayasu's arteritis) within \~1 week of treatment initiation, and
✓. Clinical indication for 18F-FDG PET-CT scan determined by the referring physician, or
✓. Undergoing surgery for LVV, or
✓. Diagnosis of LVV in remission

What they're measuring

Diagnostic accuracy of SST2 PET-MRI for LVV

Timeframe: Baseline

Trial details

NCT IDNCT04071691

SponsorUniversity of Cambridge

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-04

View on ClinicalTrials.gov More Giant Cell Arteritis trials